Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential cytokine architecture in patients treated with CART19 versus CART22.

Journal for immunotherapy of cancer·2026
Same author

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Transplantation and cellular therapy·2026
Same author

Perturbation of the preterm human immune system in early life.

JCI insight·2026
Same author

Preferences of Pediatric Patients and Their Caregivers for Chemotherapy-Induced Nausea and Vomiting Control Endpoints: A Mixed Methods Study.

Pediatric blood & cancer·2026
Same author

Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients.

HemaSphere·2026
Same author

FOXA1 and RAB25 as Biomarkers of Breast Cancer Cell Response to CYP1A1-Activated Prodrugs: Insights from CEU-938.

Pharmaceuticals (Basel, Switzerland)·2026
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
09:36

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats

Published on: October 16, 2010

Estrogen pathway polymorphisms and mammographic density.

Isabelle Dumas1, Caroline Diorio

  • 1Population Health Research Unit, FRSQ Research Center of the Quebec University Affiliated Hospital Center, Quebec City, QC, Canada.

Anticancer Research
|December 27, 2011
PubMed
Summary
This summary is machine-generated.

Single nucleotide polymorphisms in estrogen pathway genes may influence mammographic density (MD), a breast cancer risk factor. Some genetic variations appear linked to MD, particularly when considering estrogen-related factors, warranting further investigation.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Experiment Videos

Last Updated: May 26, 2026

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
09:36

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats

Published on: October 16, 2010

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Area of Science:

  • Genetics
  • Oncology
  • Endocrinology

Background:

  • Elevated mammographic density (MD) is a significant breast cancer risk factor.
  • The estrogen pathway is implicated in both breast cancer risk and MD.
  • Previous studies show inconsistent associations between circulating estrogen levels and MD.

Purpose of the Study:

  • To review the relationship between single nucleotide polymorphisms (SNPs) in estrogen pathway genes and MD.
  • To explore how estrogen-related factors might modify the association between SNPs and MD.
  • To understand the genetic basis of MD and its link to breast cancer risk.

Main Methods:

  • Systematic review of 18 studies examining SNPs in estrogen pathway genes.
  • Analysis of associations between SNPs in genes (e.g., HSD3B1, CYP1A1, ESR1) and MD.
  • Stratified analyses based on estrogen-related factors (e.g., parity, hormone replacement therapy).

Main Results:

  • Most evaluated SNPs showed no association with MD in the general population.
  • Specific SNPs in HSD17B1, COMT, UGT1A1, and ESR1 appeared associated with MD within strata of estrogen-related factors.
  • These associations, where found, aligned with the SNPs' known associations with breast cancer risk.

Conclusions:

  • The link between MD and breast cancer risk may be influenced by genetic variations in the estrogen pathway.
  • Stratified analyses considering estrogen-related factors are crucial for uncovering SNP-MD associations.
  • Further research is needed to validate these preliminary findings and understand the complex interplay of genetics, estrogen, and MD.